enow.com Web Search

  1. Ads

    related to: monoclonal antibody treatment prostate cancer bone

Search results

  1. Results from the WOW.Com Content Network
  2. Denosumab - Wikipedia

    en.wikipedia.org/wiki/Denosumab

    Denosumab, sold under the brand name Prolia among others, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone. [21] [22] The most common side effects are joint and muscle pain in the arms or legs. [23]

  3. List of therapeutic monoclonal antibodies - Wikipedia

    en.wikipedia.org/wiki/List_of_therapeutic...

    This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.

  4. Etaracizumab - Wikipedia

    en.wikipedia.org/wiki/Etaracizumab

    Etaracizumab, also known as MEDI-522, trade name Abegrin, is a humanized monoclonal antibody which is being investigated for the treatment of metastatic melanoma, prostate cancer, [1] ovarian cancer [2] and various other types of cancer. [3] It is manufactured by MedImmune. [1] It is an enhanced iteration of Vitaxin, also known as MEDI-523 ...

  5. Abituzumab - Wikipedia

    en.wikipedia.org/wiki/Abituzumab

    Abituzumab is a humanized IgG2 monoclonal antibody (mAb) targeted at CD51 (an integrin) currently in development by Merck KGaA Darmstadt, Germany in an attempt to prevent bone lesion metastases in castration-resistant prostate cancer. [1] [2]

  6. Monoclonal antibody therapy - Wikipedia

    en.wikipedia.org/wiki/Monoclonal_antibody_therapy

    Anti-cancer monoclonal antibodies can be targeted against malignant cells by several mechanisms. Ramucirumab is a recombinant human monoclonal antibody and is used in the treatment of advanced malignancies. [18] In childhood lymphoma, phase I and II studies have found a positive effect of using antibody therapy. [19]

  7. RANKL - Wikipedia

    en.wikipedia.org/wiki/RANKL

    The anti-RANKL antibody, denosumab, is also approved for use in cancer settings, and in those indications, it is branded as Xgeva. In both prostate and breast cancer, denosumab has been shown to reduce cancer treatment–induced bone loss. [21]

  1. Ads

    related to: monoclonal antibody treatment prostate cancer bone